We describe the course of 25 patients with myelofibrosis (MF) due to agnogenic myeloid metaplasia (n ¼ 19) or essential thrombocytosis (n ¼ 6) who underwent allogeneic stem cell transplantation (SCT) at one of two Canadian centers. The median age at transplantation was 48.7 (IQR 45.9-50.4) years and transplantation was carried out at a median of 10.7 (IQR 5.67-26.5) months after diagnosis. Granulocyte engraftment (absolute neutrophil count 40.5 Â 10 9 /l) occurred at a median of 20 days after transplantation for splenectomized patients, compared with 27.5 days for nonsplenectomized individuals (P ¼ 0.03). Increased risk of grade II-IV acute graft-versus-host disease (P ¼ 0.04) was noted in patients transplanted after splenectomy. Patients with MF received 0.26470.189 U of packed red blood cells per day over the first 180 days after transplantation, and remained dependent on red blood cell transfusions for a median of 123 (IQR 48-205) days. Complete remission of MF was documented in 33% of evaluable patients. The 1 year cumulative nonrelapse mortality was 48.3%. Median survival for this group of patients was 393 (IQR 109-1014+) days, with a projected 2-year overall survival of 41%. We conclude that allogeneic SCT offers a reasonable chance for prolonged survival in patients with advanced MF, but this occurs at the cost of considerable toxicity and nonrelapse mortality.
extramedullary sites. Both of these disorders may progress to bone marrow failure or acute leukemia, although patients with ET may do so more slowly than those with AMM. Once significant myelofibrosis (MF) has occurred patients may develop portal hypertension related to massive splenomegaly and succumb to infection or hemorrhage. There is no conventional curative therapy for MF, standard treatment is supportive and the goals of therapy include correction of cytopenias with transfusion of blood products and use of low-dose chemotherapy or interferon to control systemic symptoms. 1 Patients may require splenectomy because of splenic pain or mass effect, although patients with MF have increased morbidity and mortality with this procedure. 2 AMM carries the worst prognosis of any of the chronic myeloproliferative disorders, and MF is generally a late event in the course of ET. 3 Allogeneic stem cell transplantation (SCT) is an accepted form of treatment for patients with hematopoietic stem cell disorders, 4 and offers the potential for long-term resolution of MF. 5 Several case reports have documented reversal of MF [6] [7] [8] and normalization of ferrokinetic studies 9 following allogeneic SCT for this disorder. Despite these results, significant concerns have been raised regarding engraftment of allogeneic blood stem cells within a fibrotic bone marrow microenvironment. 10 More recently, it was found that engraftment times were no different in patients with and without MF. 11 In this report we describe the experience of two Canadian centers with allogeneic SCT for the treatment MF in patients with AMM or ET.
Patients and methods

Patients
Between August 1990 and June 2002, 25 adult patients with MF underwent allogeneic SCT at Princess Margaret Hospital, Toronto, Ontario and Vancouver General Hospital, Vancouver, British Columbia. Diagnoses of AMM satisfied the criteria of the Italian Consensus Conference, 12 while diagnoses of ET were based on the criteria of the Polycythemia Vera Study Group. 13 None of the patients in this study had received intensive chemotherapy for acute leukemia prior to undergoing SCT. Treatment with low-dose chemotherapy, interferon and splenectomy was at the discretion of the treating physician. Patients with ET were considered for transplantation after becoming dependent on transfusions or once systemic symptoms developed. Pretransplant characteristics are summarized in Table 1 . Nine patients had systemic symptoms and 19 patients had elevated serum lactate dehydrogenase at the time of transplantation.
Bone marrow karyotype
Cytogenetic testing was carried out on 19 patients on 23 separate occasions. Cytogenetic abnormalities were present in seven patients at diagnosis (Table 2) . Samples failed to produce dividing cells for analysis in six cases and in six cases no abnormalities were detected. Clonal evolution occurred on four occasions, three times in patients with prior cytogenetic abnormalities and once in a patient with a previously normal karyotype.
Transplant methods
The preparative regimen consisted of cyclophosphamide and total body irradiation (n ¼ 23) or oral busulfan and cyclophosphamide (n ¼ 2).
14,15 All patients received standard cyclosporine A and short-course methotrexate for acute graft-versus-host disease (GVHD) prophylaxis. 16 Stem cell source and histocompatibility results are given in Table 3 /l or at higher levels if patients were considered to be at high risk of bleeding. One unit of single donor apheresis platelets or five units of random donor platelets were given, depending upon the availability of the single donor products on the day of transfusion. Recipients in whom either member of the donor-recipient pair was positive for anti-Cytomegalovirus antibodies prior to transplantation underwent routine screening and pre-emptive therapy with ganciclovir.
Statistics
Outcomes were defined according to standard criteria. Granulocyte engraftment was taken as the first of 2 days of an absolute granulocyte count 40.5 Â 10 9 /l. Platelet engraftment was defined as the first day on which the platelet count exceeded 20 Â 10 9 /l unsupported by transfusion. GVHD was diagnosed clinically and graded according to established criteria. 17, 18 Hepatic veno-occlusive disease (VOD) was diagnosed according to the criteria of MacDonald et al 19 and graded according to the National Cancer Institute Common Toxicity Criteria. 20 The Lille score, applied retrospectively to blood counts obtained at the time of diagnosis of AMM, was used to determine each patient's risk category as described. 21 Criteria for response and progressive disease were defined prospectively as follows: complete remission (CR) was defined as the presence of normal blood counts, absence of splenomegaly on physical examination and absence of bone marrow fibrosis on bone marrow trephine biopsy. Complete remission with low platelets (CRP) was defined as for CR with the exception of a platelet count below the normal range, while remaining platelet transfusion independent. Progressive disease was defined as ongoing or recurrent evidence of a myeloproliferative disease or transformation to acute leukemia. Summary statistics such as median and interquartile range are reported in order to describe the cohort, and outcomes for which there was variable or incomplete follow-up were described according to the method of Kaplan and Meier. 22 Categorical variables were compared using Fisher's exact test, while Student's t-test was used to compare means of continuous variables.
Results
Engraftment
A total of 22 patients survived for more than 30 days and were therefore evaluable for engraftment. Of these, 20 patients achieved a neutrophil count greater than 0.5 Â 10 9 / l a median of 25 days after transplantation. Two patients (9.1%) experienced primary engraftment failure but engrafted after a second transplant from the same donor. In total, 17 patients achieved a platelet count of greater than 20 Â 10 9 /l, at a median of 35 days post-transplant. In all, 11 patients achieved a platelet count greater than 100 Â 10 9 /l at a median of 270 days after transplantation.
Neutrophil engraftment, but not platelet engraftment, was significantly affected by pretransplant splenectomy. The time to neutrophil recovery was shorter in patients who underwent transplant at any time following a splenectomy (20 days vs 27.5 days, P ¼ 0.03) (Figure 1a) . Prior splenectomy did not affect the time to platelet recovery ( Figure 1b) . Transplantation of stem cells from related or unrelated donors did not affect engraftment of neutrophils (P ¼ 0.75) or platelets (P ¼ 0.27). The impact of age at transplantation, etiology of MF, Lille score at diagnosis, presence of cytogenetic abnormalities, elevated lactate dehydrogenase, systemic symptoms and time from diagnosis of MF to SCT on neutrophil engraftment is shown in Table 4 . None of these factors influenced engraftment.
All patients required transfusion of blood products after transplantation. Detailed transfusion data were available for patients transplanted at Princes Margaret Hospital (n ¼ 17). Patients received a median of 18.5 (IQR 13
Toxicity
Hepatic VOD was diagnosed in 9/25 patients. Six patients had grade 1-2 VOD, while two patients had grade 3 and one patient had grade 4. Acute GVHD (grade II-IV) occurred in 13 patients, 5/15 related donor and 8/10 unrelated donor SCT recipients. Grade III-IV acute GVHD occurred in four recipients of transplants, all following unrelated donor SCT. In total, 17 patients survived for more than 100 days after transplant and were evaluable for chronic GVHD. Of these, 10 patients developed chronic GVHD, which was limited in four patients and extensive in six patients. Splenectomy was associated with an increased risk of grade II-IV (P ¼ 0.
04) but not grade III-IV (P ¼ NS) acute GVHD or chronic GVHD (P ¼ NS).
Five patients (20%) died of transplant-related causes in the first 100 days after SCT. The cumulative risk of transplant-related mortality over the course of the first year after SCT was 48.3%.
Response to treatment
Bone marrow biopsies were carried out on 18 patients following SCT. Only patients with repeat biopsies were evaluable for response according to the response criteria we Table 4 . None of the variables analyzed influenced the time to achieve minimal or no fibrosis. Seven of nine (78%) patients surviving for more than 1 year from the time of transplantation were free of fibrosis at the time of the last biopsy. Only three of nine (33%) patients who survived for less than 1 year showed minimal or no fibrosis on the last biopsy. CR was documented in six of 18 (33%) patients with repeat biopsies, and CRP was confirmed in two patients (11%). Both patients with CRP were receiving treatment for GVHD at the time of their most recent evaluation Three patients underwent transformation to acute leukemia 95-287 days after transplantation and died having received supportive care alone 154-393 days after their transplants. A fourth patient had persistent splenomegaly following his bone marrow transplant. Spleen size increased starting 794 days after transplantation and the patient was lost to follow-up 2695 days after transplantation, at which point he was receiving low-dose chemotherapy for splenic pain. A bone marrow biopsy at the time of increasing splenomegaly demonstrated megakaryocytic hyperplasia with no increase in blast cells.
Survival
In total, 11 patients remain alive 4.6-125+ months following transplantation (median 35 months). Nine have had follow-up bone marrow biopsies, with eight showing minimal or no fibrosis. Five surviving patients meet our criteria for CR, with two further patients showing a qualified remission with a low platelet count. The median survival for patients in this cohort was 393 days and median progression-free survival was 287 days. Survival was not influenced by pretransplant splenectomy (P ¼ 0.95) or transplantation from an unrelated donor (P ¼ 0.16). The impact of age at SCT, etiology of MF, Lille score at diagnosis, presence of cytogenetic abnormalities, elevated lactate dehydrogenase, systemic symptoms and time from diagnosis to SCT is shown in Table 4 . None of these variables influenced 2-year survival. The causes of death were progressive disease (n ¼ 3), GVHD (n ¼ 3), respiratory failure (n ¼ 3), VOD (n ¼ 2), multiorgan failure (n ¼ 2) and bowel perforation (n ¼ 1). Cases of respiratory failure were caused by Cytomegalovirus pneumonia, Pneumocystis pneumonia or diffuse alveolar hemorrhage in one case each. The actuarial 2-year survival was 41% (41.7% in ET, 41.4% in AMM; P ¼ 0.97), while progression-free survival at 2 years was 37.4% (41.7% in ET, 36.8% in AMM; P ¼ 0.86) (Figure 2 ).
Discussion
Current supportive care strategies for patients with MF have not increased survival significantly beyond the 3-5 years expected for patients with this condition. In the present study we have shown that allogeneic SCT leads to long-term disease control in some patients, although the observed treatment-related toxicity was significant.
Our criteria for complete remission in MF include reversal of fibrosis and splenomegaly and normalization of blood counts. Guardiarola et al 23 have used the term histohematological remission for the same triad of findings. The labile nature of blood counts in the post-transplant period led to the establishment of a more qualified CR, a CR with isolated low platelet counts. Using these criteria we have demonstrated the occurrence of complete remissions in six of 18 evaluable patients, while a further two Table 4 Impact of selected disease-associated and prognostic variables on outcome of stem cell transplantation for MF patients had CRP. In their study, Guardiarola et al 23 found a similar response rate and reported that such remissions were achieved in 22 out of 55 patients transplanted. None of the eight patients whom we report who achieved a CR has relapsed after a median of 35 months, suggesting that reversal of fibrosis and resumption of normal hematopoiesis may be sufficient for long-term survival in this disease.
The role of splenectomy in MF remains controversial. Splenectomy is generally reserved for patients with splenic pain or local compressive symptoms, or for patients in whom splenic sequestration is responsible for cytopenias. We have shown that neutrophil recovery occurred a median of 7 days earlier in patients who had undergone splenectomy at any time prior to transplantation, although splenectomy did not lead to improved survival in these patients. We were unable to demonstrate an effect of splenectomy on platelet recovery, although such a relation has been suggested previously. 23 Although splenectomy may be associated with beneficial effects on recovery of blood counts, it cannot be universally recommended. Recent reports suggest that the mortality rate for patients with MF undergoing splenectomy ranges between 13 and 28%, approaching the treatment-related mortality of bone marrow transplantation. 24 Furthermore, we have noted an association between prior splenectomy and grade II-IV, but not grade III-IV, acute GVHD. Although such an association has been noted in the past 25, 26 this is the first time it has been shown in patients with MF and we await confirmation of this finding in larger groups of patients.
Although patients who achieve CR may experience longterm survival, we have observed significant treatmentrelated morbidity and mortality. Patients with MF require more extensive transfusion support than other transplant recipients. Patients may continue to require transfusions of packed red blood cells for as long as 1 year after transplantation, even in the absence of major ABO blood group incompatibility. A recent review of the transfusion needs of 519 allogeneic SCT recipients treated at Princess Margaret Hospital demonstrated that patients received an average of 0.10370.12 U of packed red blood cells per day over the first 180 days after transplantation. 27 This is significantly less than the transfusion needs of the MF patients in this cohort (0.26470.189 U/day over the same time period) (Po0.0001). Cumulative treatment-related mortality was 48.3% over the course of the first year, with deaths because of the effects of the conditioning regimen, infection and GVHD predominating. The predominance of older patients with long-standing advanced disease and the high number of patients who received transplants from alternative donors in this cohort likely contributed to the high treatment-related mortality we have observed. Reports documenting the response of patients with MF to nonmyeloablative stem cell transplants suggest that this disease may be amenable to treatment with reducedintensity conditioning, 28 although patients treated in this way will continue to be at risk for GVHD and infection. The rate of recurrence of myeloproliferative disorders following non-myeloablative SCT is unknown at present.
These results suggest that allogeneic SCT is a reasonable treatment approach for patients with advanced AMM and ET complicated by MF. No other therapeutic options have the potential to reverse fibrosis and restore normal hematopoiesis in this group of patients. Furthermore, prolonged disease-free survival may be a realistic goal for patients with MF and an HLA-compatible donor. Given the high treatment-related mortality we have observed and advanced age of patients with MF in general, exploration of novel treatment strategies, such as nonmyeloablative approaches to transplantation, may be advisable to reduce treatment-related mortality. Progression-free Progression-free survival a b Figure 2 Product-limit estimates of (a) overall survival and (b) progression-free survival for recipients of allogeneic bone marrow transplants for MF because of agnogenic myeloid metaplasia and essential thrombocytosis.
